Praxis Precision Medicines, Inc.
PRAX
Κατάταξη σε μετοχές
#2647
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the... Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Τιμή μετοχής
$260.07
Κεφαλαιοποίηση
$7.26B
Αλλαγή (1 ημέρα)
7.57%
Αλλαγή (1 έτος)
36.88%
Χώρα
US
Εμπόριο Praxis Precision Medicines, Inc. (PRAX)
Κατηγορία
Healthcare
EPS για Praxis Precision Medicines, Inc. (PRAX)
EPS στις June 2026 TTM: $-12.95
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή της μετοχής της Praxis Precision Medicines, Inc., το τρέχον EPS της εταιρείας (TTM) είναι $-12.95. Στο τέλος του 2023, η εταιρεία είχε EPS $-18.69, μείωση σε σύγκριση με το EPS του 2022 που ήταν $-69.33.
Ιστορικό EPS της Praxis Precision Medicines, Inc. από 2018 έως 2026
EPS στο τέλος κάθε έτους
| Έτος | EPS | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $-12.95 | 26.84% |
| 2024 | $-10.21 | -45.37% |
| 2023 | $-18.69 | -73.04% |
| 2022 | $-69.33 | 17.59% |
| 2021 | $-58.96 | -43.09% |
| 2020 | $-103.61 | -70.25% |
| 2019 | $-348.24 | 13.53% |
| 2018 | $-306.73 | 0.00% |
EPS για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | EPS | Διαφορά EPS | Χώρα |
|---|---|---|---|
| $17.32 | -233.75% |
US
|
|
| $-7.98 | -38.38% |
US
|
|
| $-5.29 | -59.15% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -314.21% |
NL
|
